Form 8-K - Current report:
SEC Accession No. 0001370053-21-000072
Filing Date
2021-11-15
Accepted
2021-11-15 09:05:10
Documents
15
Period of Report
2021-11-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anab-20211115.htm   iXBRL 8-K 32237
2 EX-99.1 rosnilimabphase1datapressr.htm EX-99.1 26302
7 LOGO image_1a.jpg GRAPHIC 69843
  Complete submission text file 0001370053-21-000072.txt   340925

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anab-20211115.xsd EX-101.SCH 2175
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anab-20211115_def.xml EX-101.DEF 8981
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anab-20211115_lab.xml EX-101.LAB 33134
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anab-20211115_pre.xml EX-101.PRE 20654
8 EXTRACTED XBRL INSTANCE DOCUMENT anab-20211115_htm.xml XML 10999
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

IRS No.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 211406740
SIC: 2834 Pharmaceutical Preparations